Universal Vaccines:
Our first universal vaccine has completed pre-clinical development in ferrets, pigs, mice, rats and human immune organoids, and is scheduled for human clinical trials to begin in 2026. It was awarded a Gates Foundation Grand Challenge: End the Pandemic Threat. Featured in Netflix docuseries Pandemic: How to Prevent an Outbreak.
Universal Snake Antivenom:
Snakebite envenoming is a World Health Organization neglected tropical disease causing over 80,000 deaths and 300,000 permanent disabilities annually. A single broad-spectrum antivenom has not been achieved, primarily due to the complexity of snake venom and the diversity of snake species. We are developing antibody therapies to broadly neutralize the toxins in snake venom to prevent snakebite mortality and morbidity, from all snake species worldwide.
Broad-Spectrum Anti-Infectives:
Multidrug-resistant bacteria are reversing a century of medical progress made possible by the antibiotic revolution. We develop universal vaccines, as well as broad-spectrum antibody programs, in pre-clinical development and supported by the Medical Technology Enterprise Consortium, the Naval Medical Research Center, the Walter Reed Army Institute of Research, and CRADAs with the United States Army Medical Research Institute of Infectious Diseases.